Clinical Trial Update: Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial of famotidine in non-erosive gastroesophageal reflux disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease
• Non-erosive Gastroesophageal Reflux Disease

Drugs mentioned

• Famotidine (famotidine)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Gastroesophageal Reflux | Phase 2, Phase 3 | Status: COMPLETED